Red blood cell alloimmunization in sickle cell disease: the influence of racial and antigenic pattern differences between donors and recipients in Brazil

G Moreira Jr, JO Bordin, A Kuroda… - American journal of …, 1996 - Wiley Online Library
G Moreira Jr, JO Bordin, A Kuroda, J Kerbauy
American journal of hematology, 1996Wiley Online Library
Red blood cell (RBC) transfusions are widely used in the management of patients with sickle
cell disease (SCD). However, repeated RBC transfusions are often complicated by RBC
alloimmunization. To investigate whether the frequency of RBC alloimmunization could be
accounted for by racial and RBC phenotype differences between donors and recipients in
Brazil, in this study we compared the RBC phenotype of 100 SCD patients with that
observed in 120 randomly selected blood donors. A comparison of the RBC phenotype …
Abstract
Red blood cell (RBC) transfusions are widely used in the management of patients with sickle cell disease (SCD). However, repeated RBC transfusions are often complicated by RBC alloimmunization. To investigate whether the frequency of RBC alloimmunization could be accounted for by racial and RBC phenotype differences between donors and recipients in Brazil, in this study we compared the RBC phenotype of 100 SCD patients with that observed in 120 randomly selected blood donors. A comparison of the RBC phenotype between the two groups revealed a statistically significant increase in the frequency of the C antigen in the donor population (P < 0.01), but no significant difference was observed for the A, B, D, c, E, e, K, k, Fya, M, N, S, s, and Jka antigens. Using standard techniques (indirect antiglobulin test, enzyme treatment, and low‐ionic‐strength solution) we observed an RBC alloimmunization rate of 12.9% (11/85) in the SCD patients. Fifteen alloantibodies were detected in 11 patients, and most (80%) involved antigens in the Rhesus and Kell systems. This observed RBC alloimmunization rate in SCD patients in Brazil is lower than that reported by studies from North America, suggesting that the requirement for extended antigen‐matched RBC transfusion for SCD patients in the setting of a RBC phenotype concordant donor‐recipient population may not be cost‐effective in some countries. © 1996 Wiley‐Liss, Inc.
Wiley Online Library
以上显示的是最相近的搜索结果。 查看全部搜索结果